Standard and High Dose Irinotecan Based on UGT1A1 Genotype for First-line Treatment of Locally Advanced Colon Cancer

NCT01826396 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Colonic Neoplasms

Interventions

DRUG: Irinotecan

Sponsor

Colorectal Cancer Institute of the Heilongjiang Academy of Medical Sciences